Navigation Links
Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
Date:3/5/2009

TUSTIN, Calif., March 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the third quarter of fiscal year 2009 on March 12, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Peregrine's senior management will discuss financial results for the third quarter ended January 31, 2009 and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/ 8:30 a.m. PDT. To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 19, 2009 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manuf
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
2. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
3. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
6. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
9. Ferring Pharmaceuticals Announces Immediate Availability of Degarelix for the Treatment of Advanced Prostate Cancer
10. Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth
11. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... of Medicine at the University of Pennsylvania in collaboration ... $8 million grant from the National Cancer Institute (NCI) ... in patients with malignant pleural mesothelioma, a rare, aggressive ... the lining of the lungs and is caused almost ... a clinical trial and additional studies looking at the ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... of lung cancer, researchers have uncovered mutations in a ... The new knowledge may expand treatments for patients because ... available or are in clinical trials. , Reporting July ... Genome Atlas (TCGA), including researchers at Washington University School ... other institutions, studied tumors from 230 patients with lung ...
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3
... groundbreaking program,dealing with the deteriorating physical, mental and ... gender specific psychological and,medical needs will take place ... under the auspices of members of the Westchester,medical ... J. Legato,M.D. and Lionel Tiger, Ph.D., Dr. ...
... Experts develop sequence of instructions they say could help doctors ... safety experts say that almost all kids who are allergic ... set of standard precautions. , Reporting in the September ... by the Johns Hopkins Children,s Center put forth a step-by-step ...
... Martin Schiff, M.D.,is an illustrious member and recognized authority ... career is detailed in "Who,s Who in,California," "Who,s Who ... in,the World," "Who,s Who in Medicine and Health Care" ... to devote his expertise to exposing the,inaccurate, misleading theories ...
... Coast states are open, CVS/pharmacy will also donate water, ice, diapers and ... communities impacted by Hurricane Gustav, ... in Louisiana have re-opened since Hurricane Gustav,in the following cities and towns:, ... City Broussard Covington Cutoff Destrehan Franklinton ...
... 4 In some countries, lime juice is,thought to ... Against such a backdrop of misinformation and stigma, ... killed tens of millions,of people?, Part of the ... news media, says,Internews Network, an international media development nonprofit ...
... SAFC Pharma(TM), a focus,area within SAFC(R) ( ... SIAL ), today officially announced details,of a ... facility,designed to significantly increase its capacity to produce ... investment,includes the purchase of 15 acres of green ...
Cached Medicine News:Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2Health News:CVS/pharmacy Re-Opens 64 Stores in Louisiana 2Health News:More than 1,000 Journalists Enlisted in Fight Against HIV/AIDS 2Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 2Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 3
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Oct. 16 AngioGenex Inc. (OTC,Bulletin Board: AGGX.OB) ... molecules that are potent inhibitors of the Id ... filing of this patent,constitute major milestones in the ... Dr. Richard Salvador, President and CEO, and the,former ...
... Oct. 16 When eighty-six-year-old,Keith Hora went to see ... University of Newcastle in Australia, he was told he ... been diagnosed with stage III melanoma, one,of the most ... had multiple melanoma reoccurrences in the previously treated,area of ...
Cached Medicine Technology:AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer 2Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years 2
Inorganic phosphorus (UV method) reagent is for the quantitative determination of inorganic phosphorus in human serum....
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
For the kinetic quantitative determination of g-Glutamyl Transferase in serum for manual and/or automated procedures....
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Medicine Products: